مباشر

FierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment FierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies Endpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff Clinical OMICsRewriting Cancer Care Through Epigenetics FierceBiotechTraws defers midphase flu study after negative regulatory review Endpoints NewsSix leaders working on LGBTQ+ inclusion in biopharma BioWorldEnsem Therapeutics patents new GTPase KRAS mutant inhibitors BioWorldCaregen reports new GLP-1R agonists BioWorldIteos Belgium discloses new PTPN1/2 inhibitors BioWorldJiangsu Aidea Pharmaceutical identifies amide compounds for HIV BioWorldNew SOS1 inhibitors divulged in Sichuan Huiyu patent

Eli Lilly ٣٠ أبريل ٢٠٢٦

Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch - BioPharma Dive

Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch - BioPharma Dive

المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.